Rockwell Medical, Inc. (RMTI) Q3 2024 Earnings Call Transcript
Rockwell Medical, Inc. (NASDAQ:RMTI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President & Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President of Finance Conference Call Participants Anthony Venditti - Maxim Group Operator Good morning and welcome to Rockwell Medical's Third Quarter 2024 Results Conference Call and Webcast. Please note, this event is being recorded.
Rockwell Medical (RMTI) Surpasses Q3 Earnings and Revenue Estimates
Rockwell Medical (RMTI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.07 per share a year ago.
RMTI Stock Rises 138% in Q3: What Should You Do Ahead of Earnings?
Rockwell Medical expects its Q3 results to gain from a high rate of customer conversions toward it compared with its primary competitor.
Rockwell Medical on Expansion Spree: Should You Buy the Stock Now?
This year can be regarded as a momentous period for RMTI's business because this is the first time in its history that it has achieved steady revenue growth.
Rockwell Medical (RMTI) Upgraded to Buy: Here's Why
Rockwell Medical (RMTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rockwell Medical, Inc. (RMTI) Hits Fresh High: Is There Still Room to Run?
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rockwell Medical Stock Surges 108.5% YTD: Should You Snap it Up Now?
RMTI continues to outperform its peers, banking on its focus on optimizing business to drive sustainable profitability and meaningful cash flow generation.
Rockwell Medical: The Turnaround Is Looking Real
Rockwell develop concentrates for hemodialysis, which is a process that seeks to artificially replace kidney function in patients with chronic failure. Despite being a critical product, there's currently no large competitor dominating the category and the company is a leader. After years of constant CEO turnover and poor results, Mr. Mark Strobeck has turned around and has already reached its first profitable quarter ever.
Rockwell Medical (RMTI) is a Great Momentum Stock: Should You Buy?
Does Rockwell Medical (RMTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Fast-paced Mover Rockwell Medical (RMTI) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Rockwell Medical, Inc. (RMTI) Hit a 52 Week High, Can the Run Continue?
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rockwell Medical, Inc. (RMTI) Hits Fresh High: Is There Still Room to Run?
Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
